Examples of this are the small molecule EGFR tyrosine kinase inhibitors, which enhance survival in lung cancer but are ineffective in glioblastoma [12, 13], even though EGFR is amplified and mutated to a constitutively active form in many glioblastomas. Here, EGFR is linked to glioblastoma.